Mannello Ferdinando, Tonti Gaetana A M, Medda Virginia, Pederzoli Andrea, Sauter Edward R
Department of Biomolecular Sciences, Section of Clinical Biochemistry, University Carlo Bo, Urbino PU, Italy.
Cancer Sci. 2008 Nov;99(11):2160-9. doi: 10.1111/j.1349-7006.2008.00921.x. Epub 2008 Sep 22.
Breast cancer, a worldwide disease with increasing incidence, develops from ductal/lobular epithelium. Nipple aspirate fluid (NAF), secreted from the breast ducts and lobules, can be analyzed to assess breast metabolic activity. P-cadherin is frequently over-expressed in high-grade invasive breast carcinomas and has been reported to be an enhancer of migration and invasion of breast cancer cells, being correlated with tumor aggressiveness. The present study analyzed the soluble fragment of P-cadherin in milk, NAF and matched plasma samples of healthy subjects and in women with precancer conditions and breast cancer. Soluble P-cadherin was detected in all plasma and milk samples, and in about 31.3% of NAF samples. The lowest levels of soluble P-cadherin were found in plasma, with no significant difference among NoCancer, PreCancer and Cancer patients. The highest concentration of soluble P-cadherin was detected in milk collected during the first trimester of lactation, significantly with respect to all NAF samples. There were significantly higher levels of soluble P-cadherin in NAF from Cancer patients than those in women with NoCancer and PreCancer (P < 0.0001). Although no significant difference was found between in situ and invasive breast cancer, soluble P-cadherin levels were found at high concentrations in c-erbB-2-positive tumors, showing a positive correlation with disease stage grouping and tumor grade, and an inverse relationship with estrogen/progesterone receptor status. High levels of the soluble fragment of P-cadherin in Cancer NAF suggest its possible release via proteolytic processing, favoring cancer cell detachment from breast duct, and suggesting that measuring soluble P-cadherin in NAF may improve the identification of women with increased breast cancer risk.
乳腺癌是一种全球发病率不断上升的疾病,起源于导管/小叶上皮。从乳腺导管和小叶分泌的乳头抽吸液(NAF)可用于分析,以评估乳腺代谢活性。P-钙黏蛋白在高级别浸润性乳腺癌中经常过度表达,据报道它是乳腺癌细胞迁移和侵袭的增强因子,与肿瘤侵袭性相关。本研究分析了健康受试者、癌前病变女性和乳腺癌患者的乳汁、NAF及匹配血浆样本中P-钙黏蛋白的可溶性片段。在所有血浆和乳汁样本以及约31.3%的NAF样本中检测到可溶性P-钙黏蛋白。血浆中可溶性P-钙黏蛋白水平最低,在无癌、癌前病变和癌症患者之间无显著差异。哺乳期头三个月采集的乳汁中可溶性P-钙黏蛋白浓度最高,与所有NAF样本相比有显著差异。癌症患者NAF中的可溶性P-钙黏蛋白水平显著高于无癌和癌前病变女性(P < 0.0001)。尽管原位癌和浸润性乳腺癌之间未发现显著差异,但在c-erbB-2阳性肿瘤中可溶性P-钙黏蛋白水平较高,与疾病分期分组和肿瘤分级呈正相关,与雌激素/孕激素受体状态呈负相关。癌症患者NAF中高水平的P-钙黏蛋白可溶性片段表明其可能通过蛋白水解加工释放,有利于癌细胞从乳腺导管脱离,这表明检测NAF中的可溶性P-钙黏蛋白可能有助于提高对乳腺癌风险增加女性的识别。